Immunomedics Announces Combo of 90Y-Epratuzumab-Veltuzumab is Active in … – Benzinga
Immunomedics Announces Combo of 90Y-Epratuzumab-Veltuzumab is Active in …Benzinga1 Moreover, given that the anti-CD20 veltuzumab also compared well to published results with rituximab,^2,3 the Company is conducting a Phase I/II study to evaluate the …
